Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
2
Phase 1 Data: SNTX-2643 Blunts the Brain's Stress Response After a Single Dose
3
Recognizing Negative and Cognitive Symptoms in Schizophrenia Care
4
Rethinking 'Stable': The Case for Measurement-Based Care in Schizophrenia
5